A new experimental drug called daraxonrasib is showing unprecedented results in treating advanced pancreatic cancer, more than doubling median survival times for patients who have already undergone chemotherapy. The treatment targets mutations of the KRAS gene, which drives more than 90 percent of pancreatic cancers and has long been considered undruggable by researchers.
Pancreatic cancer is expected to kill more than 52,000 Americans this year. The disease is often diagnosed after it has spread, leaving patients with a five-year overall survival rate of just 13 percent. For most advanced-stage patients, there has been no cure beyond chemotherapy—until now, according to researchers involved in the clinical trials.
What the Left Is Saying
Progressive health policy advocates are calling for immediate action to ensure the drug will be accessible and affordable once approved. They point to the high costs of similar targeted cancer therapies, which can reach tens of thousands of dollars per month, as evidence that without intervention, the treatment could remain out of reach for many patients who need it.
Representative Jan Schakowsky, a Democrat from Illinois who has championed healthcare affordability legislation, said in a statement that "breakthroughs like this mean nothing if they're locked behind paywalls." She called on the Biden administration to begin negotiating coverage terms with the drug's manufacturer before FDA approval is finalized. "Medicare and Medicaid patients deserve priority access to these life-extending treatments," Schakowsky wrote.
Progressive advocacy groups, including Patients For Affordable Drugs, argue that federal investment in cancer research through the National Cancer Institute helped make this breakthrough possible. They contend that taxpayers who funded the underlying science should not be forced to pay again at high prices when the drug reaches market. Consumer protections limiting out-of-pocket costs for Medicare beneficiaries remain a key legislative priority, according to the group.
What the Right Is Saying
Conservative healthcare policy experts are emphasizing the innovation ecosystem that made this breakthrough possible and cautioning against price controls they say would stifle future research. They point to the decades of private-sector investment in KRAS targeting as evidence that market incentives work.
Senator Bill Cassidy of Louisiana, a Republican who serves on the Senate Health Committee, praised the development in remarks to reporters. "This is what happens when we let science and innovation thrive," he said. Cassidy has opposed drug price negotiation provisions in previous legislation, arguing that government interference in pricing discourages the risky research investments needed for future breakthroughs.
The American Enterprise Institute, a conservative think tank, released an analysis noting that daraxonrasib represents the culmination of over 40 years of RAS oncogene research. The group's health policy director wrote that "regulatory efficiency at FDA" under existing accelerated approval pathways should be credited alongside the scientific achievement. The analysis cautioned against adding new pricing regulations to any legislative packages addressing this drug, arguing such measures would reduce investment in similar cancer treatments currently in development.
What the Numbers Show
The Phase 2 clinical trial data showed patients taking daraxonrasib lived a median of 13 months compared to six months for those receiving standard treatment only. This represents a 117 percent improvement in progression-free survival—a result researchers called unprecedented in treating stage four pancreatic cancer.
Approximately 90 to 93 percent of pancreatic cancer patients carry KRAS mutations, making the drug potentially applicable to a broad patient population. The study included all comers regardless of specific mutation status and showed efficacy across subgroups. Only a small percentage of trial participants discontinued the drug due to side effects, though some patients reported severe skin reactions described as feeling nuclear by former Senator Ben Sasse, who has been taking the drug since his diagnosis.
The FDA has granted early access to the drug for certain patients while the company pursues expedited approval. If approved, the treatment would require a prescription from an oncologist and ongoing monitoring for side effects that include rash, which researchers say can be managed with dermatological support and prophylactic measures.
The Bottom Line
Daraxonrasib represents what researchers are calling a game changer in pancreatic cancer treatment, marking the first time a KRAS-targeting drug has shown meaningful survival benefits in this disease. The FDA's accelerated approval pathway may allow the drug to reach patients faster than traditional timelines, though widespread insurance coverage decisions would follow.
The broader implications extend to other cancers with KRAS mutations, including certain colon and lung cancers where similar drugs are already available. Researchers say daraxonrasib could become the standard second-line treatment for pancreatic cancer after one prior chemotherapy regimen. Patient advocates on both sides of the political spectrum agree that access and affordability will be critical issues once the drug receives approval—the debate is likely to shift from whether this breakthrough matters to who should pay for it and how.